Is it Too Late to Buy Gold?
Amid deep uncertainties about the future of the US economy,…
Sell
29
CTNM Quote, Financials, Valuation and Earnings
Last price:
$4.51
Seasonality move
:
35.9%
Day range:
$4.31 - $4.51
52-week range:
$3.85 - $22.00
Dividend yield:
0%
P/E ratio:
50.95x
P/S ratio:
--
P/B ratio:
0.59x
Volume:
51.3K
Avg. volume:
76.2K
1-year change:
-71.37%
Market cap:
$116.4M
Revenue:
$50M
EPS (TTM):
-$1.66
Analysts' Opinion
-
Consensus RatingContineum Therapeutics has received a consensus rating of Buy. The company's average rating is a Buy based on 3 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $24.80, Contineum Therapeutics has an estimated upside of 451.11% from its current price of $4.50.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $16.00 representing 100% downside risk from its current price of $4.50.
Fair Value
-
According to the consensus of 3 analysts, Contineum Therapeutics has 451.11% upside to fair value with a price target of $24.80 per share.
CTNM vs. S&P 500
-
Over the past 5 trading days, Contineum Therapeutics has underperformed the S&P 500 by -11.61% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Contineum Therapeutics does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Contineum Therapeutics has grown year-over-year revenues for 0 quarters straight. In the most recent quarter Contineum Therapeutics reported revenues of --.
Earnings Growth
-
Contineum Therapeutics has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Contineum Therapeutics reported earnings per share of -$0.56.
Enterprise value:
-88.3M
EV / Invested capital:
--
Price / LTM sales:
--
EV / EBIT:
13.73x
EV / Revenue:
--
PEG ratio (5yr expected):
--
EV / Free cash flow:
2.65x
Price / Operating cash flow:
23.72x
Enterprise value / EBITDA:
13.60x
Gross Profit (TTM):
--
Return On Assets:
--
Net Income Margin (TTM):
--
Return On Equity:
--
Return On Invested Capital:
--
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Income Statement | ||||||
| Revenue | -- | -- | -- | -- | -- | |
| Gross Profit | -- | -- | -- | -- | -- | |
| Operating Income | -- | $16.1M | -$50.9M | -$9.7M | -$17M | |
| EBITDA | -- | $23.6M | -$42M | -$7.9M | -$14.5M | |
| Diluted EPS | -- | $0.33 | -$1.66 | $0.68 | -$0.56 | |
| Period Ending | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | -- | -- | $48.4M | $127.7M | $206.4M | |
| Total Assets | -- | -- | $50.6M | $130.4M | $212.8M | |
| Current Liabilities | -- | -- | $7.6M | $5.5M | $10M | |
| Total Liabilities | -- | -- | $143.8M | $198.3M | $14.8M | |
| Total Equity | -- | -- | -$93.2M | -$67.9M | $198.1M | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -- | $19.3M | -$32.8M | -$10.7M | -$10.2M | |
| Cash From Investing | -- | -$65.6M | -$69.7M | $9M | -$9.4M | |
| Cash From Financing | -- | $56.2M | $109M | -$321K | $642K | |
| Free Cash Flow | -- | $18.9M | -$33.4M | -$11M | -$10.4M | |
CTNM
Sector
Market Cap
$116.4M
$34.4M
Price % of 52-Week High
20.46%
44.25%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.82%
1-Year Price Total Return
-71.37%
-39.44%
Beta (5-Year)
--
0.738
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$4.63
200-day SMA
Sell
Level
$13.83
Bollinger Bands (100)
Sell
Level
5.91 - 13.13
Chaikin Money Flow
Sell
Level
-259.9K
20-day SMA
Sell
Level
$5.01
Relative Strength Index (RSI14)
Sell
Level
35.39
ADX Line
Sell
Level
45.28
Williams %R
Neutral
Level
-65.7895
50-day SMA
Sell
Level
$6.35
MACD (12, 26)
Buy
Level
0.24
25-day Aroon Oscillator
Sell
Level
-64
On Balance Volume
Sell
Level
-306.5K
Financial Scores
--
Altman Z-Score
(Annual)
Level (--)
--
CA Score
(Annual)
Level (--)
--
Beneish M-Score
(Annual)
Level (--)
--
Momentum Score
Level (--)
--
Ohlson Score
Level (--)
--
Piotroski F Score
(Annual)
Level (--)
--
Quality Ratio Score
Level (--)
--
Fundamental Score
Level (--)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Contineum Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for NI&I indications with high unmet need. Its internally-discovered drug candidates, PIPE-791 and PIPE-307, PIPE-791, is a novel, brain penetrant, small molecule inhibitor of the LPA1R in development for IPF and PIPE-307, is a novel, small molecule selective inhibitor of the muscarinic type 1 M1R, in development for depression and RRMS.
Stock Forecast FAQ
In the current month, CTNM has received 3 Buy ratings 0 Hold ratings, and 0 Sell ratings. The CTNM average analyst price target in the past 3 months is $24.80.
-
Where Will Contineum Therapeutics Stock Be In 1 Year?
According to analysts, the consensus estimate is that Contineum Therapeutics share price will rise to $24.80 per share over the next 12 months.
-
What Do Analysts Say About Contineum Therapeutics?
Analysts are divided on their view about Contineum Therapeutics share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Contineum Therapeutics is a Sell and believe this share price will drop from its current level to $16.00.
-
What Is Contineum Therapeutics's Price Target?
The price target for Contineum Therapeutics over the next 1-year time period is forecast to be $24.80 according to 3 Wall Street analysts, 3 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is CTNM A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Contineum Therapeutics is a Buy. 3 of 3 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of CTNM?
You can purchase shares of Contineum Therapeutics via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Contineum Therapeutics shares.
-
What Is The Contineum Therapeutics Share Price Today?
Contineum Therapeutics was last trading at $4.51 per share. This represents the most recent stock quote for Contineum Therapeutics. Yesterday, Contineum Therapeutics closed at $4.50 per share.
-
How To Buy Contineum Therapeutics Stock Online?
In order to purchase Contineum Therapeutics stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is NextEra Energy a Stock to Hold Forever?
NextEra Energy (NYSE:NEE) share price sold off hard in recent…
Why Did Bill Ackman Buy Alphabet Stock?
Bill Ackman has become famous in the investing world for…
Stock Ideas
Buy
61
Is AAPL Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 35x
Buy
55
Is MSFT Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 33x
Buy
54
Is NVDA Stock a Buy?
Market Cap: $2.7T
P/E Ratio: 37x
Alerts
Sell
39
RGC alert for Apr 29
Regencell Bioscience Holdings [RGC] is down 6.79% over the past day.
Buy
76
EXOD alert for Apr 29
Exodus Movement [EXOD] is down 2.32% over the past day.
Sell
48
SBGSY alert for Apr 29
Schneider Electric SE [SBGSY] is down 0.47% over the past day.
